MG1-MAGEA3
AXP000121.1 · Oncolytic virus
- Platform
- Maraba virus MG1 (double-mutant, recombinant)
- Originator
- Ottawa Hospital Research Institute (John Bell)
- Sponsor
- Turnstone Biologics
Names
| Name | Type | Source |
|---|---|---|
| MG1-MAGEA3 | preferred name, code | curator, ctgov |
| MG1MA3 | code | ncit |
| MG1 Maraba/MAGE-A3 | synonym | ncit |
Virus
- Role
- Oncolytic
- Family
- Rhabdoviridae
- Virus
- Maraba virus (NCBI Taxonomy 1046251)
- Strain
- MG1 (G Q242R, M L123W)
- Replication
- replicating
- Modifications
- attenuating G and M mutations (MG1 backbone); MAGE-A3 transgene inserted
- Transgenes
- MAGEA3
- Route
- intravenous
- Source
- evidence
Cross-references
- NCI Thesaurus
- C118973
Approvals
No regulatory approval recorded.
Clinical trials (3)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT03773744 | MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma | Withdrawn | Phase 1 | 2020-02-15 | 2020-10-30 | 0 | Metastatic Melanoma; Squamous Cell Skin Carcinoma |
| NCT02879760 | Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients | Completed | Phase 1/2 | 2017-03-08 | 2020-02-15 | 16 | Non-Small Cell Lung Cancer |
| NCT02285816 | MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours | Active not recruiting | Phase 1/2 | 2015-01-22 | 2019-09-19 | 56 | Advanced/Metastatic Solid Tumours |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40389376 | Oncolytic VSV-IL-2 has enhanced anticancer vaccination adjuvant abilities. | Journal for immunotherapy of cancer | 2025 | cited by trial NCT02285816 |
| PMID 33608375 | In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity. | Journal for immunotherapy of cancer | 2021 | cited by trial NCT02285816 |
| PMID 30546947 | Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials. | Oncoimmunology | 2019 | cited by trial NCT02285816 |
Notes
Maraba MG1 (G protein Q242R, M protein L123W) encoding MAGE-A3, given as a boost after an adenoviral Ad-MAGEA3 prime. Ad-MAGEA3 is a separate adenoviral construct and belongs to the adenovirus group, not entered here. Turnstone deprioritised the MG1 programme; NCT03773744 was withdrawn.
How to cite
MG1-MAGEA3 (AXP000121.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000121.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.